Healthcare enterprises are now optimistically eyeing life after the worst of the COVID crisis, applying lessons learned and re-examining strategies.
In summer 2022, UPS Healthcare released the results of Vital Signs, a survey assessing where decision-makers in healthcare see the industry now. The survey engaged 600 director-level and above, healthcare supply chain and logistics professionals in North America, Europe, the Middle East, Africa and Asia-Pacific.
In three important segments – pharmaceuticals, laboratories and medical device manufacturing – distinct post-pandemic priorities have emerged. Overall, end-to-end supply chain connectivity is in demand. Cold chains will be more and more vital to success ... along with real-time temperature monitoring. And, holistic logistics driven by technology will be in demand.
These priorities can be broadly summarised in three categories:
‘In a post-pandemic world, we expect healthcare logistics leaders will increasingly make decisions based on the adaptability, visibility, and scalability features offered by logistics partners’, says Shannon DeMar, Director of Strategy, UPS Healthcare.
With new post-pandemic industry priorities, strategists in pharmaceuticals, medical device manufacturing and laboratories have been analysing their unique situations and challenges.
The Vital Signs study offers insights on their logistics/partnerships thinking.
Pharmaceutical firms are prioritising compliance, cold chain costs and portfolios.
‘Pharma companies have made significant investments in new technology, and they are primed for growth’, says DeMar, ‘but they have also faced increased scrutiny over their ability to deliver therapeutics equitably and at scale. Their ability to coordinate global Governmental regulatory environments is increasing as well. To deliver products globally, large and small manufacturers must navigate a web of laws and compliance directives.’
The Vital Signs survey suggests pharma companies in the short term (1-2 years) will focus on
The focus on portfolio reduction likely means successful products will see new investment and scale-up.
Longer term (5-10 years), Vital Signs indicates that companies will prioritise:
All the above suggest they anticipate growth. Other noteworthy long-term priorities include cold chain costs (20%) and home health (17%), driving the need for logistics partners who can facilitate.
Download Vital Signs for Pharma
Laboratories are prioritising cost controls and expansion.
‘Demand for lab services was already on the rise before the pandemic. Advancements in healthcare/consumer technology before and during the pandemic resulted in many home-based healthcare services relying on outsourced labs’, says DeMar.
‘The number of labs has actually doubled since 2019 – we have 31,000 today. Labs in the United States alone will do 14 billion diagnostic tests this year. This market will be valued at $75 billion by 2027."
Short-term (1-2 years), strategic priorities in the lab sector are:
This indicates that labs mean to improve return-on-investment and operation efficiencies as they generate new revenue through expanded testing capabilities.
In the next 5-10 years, strategic priorities are:
‘The focus on home nurse availability confirms that home-based care continues to emerge as a priority’, says DeMar. ‘As healthcare systems struggle with staff shortages, home care will take on more importance ... and that means labs will compete with hospitals and facilities for nursing staff to perform home-based sample collection and on-site testing.’
Download Vital Signs for Laboratories
Medical device manufacturers are prioritising cost reduction, technology and expansion.
‘Not long ago, the medical device industry was one of the fastest-growing sectors in healthcare’, says DeMar. ‘Much of the technology making contemporary medical devices possible was relatively new. While the market has stabilised some, firms expect the sector to still grow significantly as at-home and personalised medical care gain prominence."
Vital Signs reveals the short-term focus:
Long-term focus differs. Device manufacturers report the following as top sector priorities:
Other priorities include reducing logistics costs (26%) and expanding a product portfolio (25%).
Download Vital Signs for Medical Device
Post-pandemic priorities have evolved.
The Vital Signs survey shows pharmaceutical, medical device manufacturers, and laboratories shifting focus to adaptability, visibility, and scalability ... with a close eye on cost reduction and innovation.
‘This survey suggests that enterprises in these sectors are most interested in finding a reliable partner who will provide them with real-time visibility into their supply and logistics networks’, says DeMar, ‘as well as scalable solutions that help them solve problems for their businesses ... and for the patients who rely on their products.’
It’s not a sample, it’s a somebody
UPS Healthcare invests for the next phase of European healthcare
Building on-ramps to the Age of Biologics